Thor Medical Stock Nasdaq Stockholm
Stocks
NANOVO
NO0010597883
Biotechnology & Medical Research
OTC Markets Traded|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.275 NOK | -2.84% |
|
+9.32% | -13.89% |
| Market Cap | 1.53B 154M 135M 124M 116M 219M 14.64B 223M 1.5B 580M 7.19B 578M 566M 25.02B | P/E 2026 * |
-30.3x | P/E 2027 * | -38.5x |
|---|---|---|---|---|---|
| Enterprise Value | 1.71B 172M 151M 139M 130M 245M 16.4B 250M 1.68B 650M 8.05B 648M 634M 28.01B | EV / Sales 2026 * |
34.9x | EV / Sales 2027 * | 10.1x |
| Free-Float |
59.77% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Thor Medical
| 1 week | +9.32% | ||
| 3 months | -2.44% | ||
| 6 months | -17.14% | ||
| Current year | -13.89% |
| 5 years | 1.05 |  | 28.72 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jasper Kurth
CEO | Chief Executive Officer | 41 | 2024-07-31 |
| Director of Finance/CFO | 37 | 2023-06-30 | |
Sindre Hassfjell
CTO | Chief Tech/Sci/R&D Officer | - | 2023-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Ramdahl
BRD | Director/Board Member | 70 | 2025-04-23 |
| Director/Board Member | 67 | 2023-06-27 | |
John Andersen
CHM | Chairman | 59 | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.84% | +9.32% | +74.95% | - | 154M | |
| +1.71% | +3.25% | +72.55% | +131.02% | 56.21B | |
| +0.55% | +8.49% | +77.09% | +100.93% | 55.38B | |
| +0.93% | +4.11% | -12.64% | -12.98% | 23.75B | |
| +0.36% | +3.42% | +9.61% | +407.11% | 23.19B | |
| +3.64% | +8.34% | +39.81% | -5.88% | 18.14B | |
| +1.47% | +6.30% | +41.17% | -29.44% | 16.84B | |
| +1.49% | +17.24% | +174.91% | +344.55% | 15.86B | |
| -0.83% | +2.06% | +23.70% | +182.37% | 13.56B | |
| +7.20% | +13.33% | +42.13% | - | 12.97B | |
| Average | +1.84% | +6.94% | +54.33% | +139.71% | 26.21B | |
| Weighted average by Cap. | +1.50% | +6.60% | +56.50% | +131.98% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 49M 4.94M 4.34M 4M 3.72M 7.02M 470M 7.16M 48.06M 18.62M 231M 18.56M 18.16M 803M | 168M 16.95M 14.88M 13.7M 12.77M 24.08M 1.61B 24.57M 165M 63.84M 791M 63.65M 62.27M 2.75B |
| Net income | -49M -4.94M -4.34M -4M -3.72M -7.02M -470M -7.16M -48.06M -18.62M -231M -18.56M -18.16M -803M | -40M -4.04M -3.54M -3.26M -3.04M -5.73M -384M -5.85M -39.23M -15.2M -188M -15.15M -14.83M -656M |
| Net Debt | 183M 18.47M 16.21M 14.92M 13.91M 26.23M 1.76B 26.76M 179M 69.54M 862M 69.33M 67.83M 3B | 177M 17.86M 15.68M 14.43M 13.45M 25.37M 1.7B 25.88M 174M 67.26M 833M 67.06M 65.61M 2.9B |
Employees
-
Calendar
08-28 -
Earnings release - Q2 2026
| Date | Price | Change |
|---|---|---|
| 26-06-26 | NOK 4.400 | +9.32% |
Sell
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
4.240NOK
Average target price
3.500NOK
Spread / Average Target
-17.45%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- NANOV Stock
- NANOVO Stock
Select your edition
All financial news and data tailored to specific country editions
